AstraZeneca IP Suit Survives Generics Co.'s Application Swap
A Delaware federal judge has ruled that AstraZeneca's patent infringement suit against Wockhardt over planned generic versions of AstraZeneca diabetes drugs can proceed, even though Wockhardt last month told regulators it...To view the full article, register now.
Already a subscriber? Click here to view full article